The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Naotoshi Sugimoto
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Junji Tanaka
No relevant relationships to disclose
Masahiro Tsuda
No relevant relationships to disclose
Wataru Okamoto
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Hiroshi Imamura
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Yukinori Kurokawa
Honoraria - Taiho Pharmaceutical
Yoshito Komatsu
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Chikashi Ishioka
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Asahi Kasei ; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Novartis; Ono Pharmaceutical ; Taiho Pharmaceutical; Takeda; Yakult Honsha
Toshimasa Tsujinaka
Honoraria - Taiho Pharmaceutical
Hiroya Takiuchi
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Hiroshi Furukawa
No relevant relationships to disclose